EVOK Expects Data In Q3, PRTA Has Its Hands Full, SUPN Awaits FDA Decision

Prothena Corp. plc (PRTA) has a couple of catalysts to watch out for in the coming months, related to its three lead protein immunotherapy programs - NEOD001, PRX002 and PRX003.

from RTT - Biotech http://ift.tt/1SMDUtB
via IFTTT